Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note released on Thursday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

NYSE BTX opened at $0.21 on Thursday. The stock’s 50 day simple moving average is $1.17 and its 200 day simple moving average is $1.62. Brooklyn ImmunoTherapeutics has a one year low of $0.17 and a one year high of $10.10. The firm has a market cap of $12.07 million, a PE ratio of -0.37 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.